SecBot SecBot
8-K ·Filed May 13, 2026

AIMDW

Ainos, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001493152-26-022751
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The 99.8% revenue drop confirms AI Nose commercialization is not yet generating meaningful sales. Traders should watch for any new deployment announcements or customer contracts to validate the second-half recovery narrative. The stock's micro-cap status (<$1M) means high volatility; any positive news could trigger outsized moves, but the fundamental trajectory remains negative.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
AIMDW ▲ 0.00% at T+20d
SHORT call ✗ call lost 0.00% · α vs SPY -0.86% · entry $0.1008 → $0.1008
Next anchor: T+60d due 3mo ago
Entry = T+0 close
May 13, 2026
via day close
T+1d
0.00%
call 0.00% · α -1.23%
$0.1008
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.72%
$0.1008
settled 5mo ago
T+20d
0.00%
call 0.00% · α -0.86%
$0.1008
settled 5mo ago
T+60d
Pending
due 3mo ago

Price Chart

Loading chart...

Executive Summary

Ainos reported Q1 2026 revenue of $161, a 99.8% decline YoY from $106,207, with a net loss of $2.46M (improved from $3.29M). The company remains in early commercialization with no meaningful revenue, despite a $2.8M financing boosting cash to $2.84M. The dramatic revenue collapse signals continued struggle to generate commercial traction.

Key Financial Metrics

Revenue
$161.00
est $0.00 · -99.8% YoY
Gross Margin
-373.9%

Key Facts

  • Q1 2026 revenue collapsed to $161 from $106,207 in Q1 2025, a 99.8% decline
  • Gross loss of $602 vs gross profit of $87,974 in prior year
  • Operating expenses decreased 30% to $2.28M from $3.25M
  • Net loss improved to $2.46M from $3.29M
  • Cash increased to $2.84M from $0.42M after $2.8M financing

Financial Impact

Revenue decline of ~$106k (99.8% YoY) and continued operating losses of $2.28M per quarter

revenuegross profitoperating expenses

Risk Factors

  • Continued revenue decline or stagnation in Q2 2026
  • Need for additional dilutive financing if cash burn persists
  • Failure to convert pilot deployments into commercial revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-022751
Document: form8-k.htm0001493152-26-022751
Document: 0001493152-26-022751-index-headers.html0001493152-26-022751
Document: 0001493152-26-022751-index.html0001493152-26-022751
Document: 0001493152-26-022751.txt0001493152-26-022751
8-K Data (Synthetic)0001493152-26-022751

US Market Status

Market Closed — Opens in 4h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026